Standout Papers
- Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents (2018)
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial (2020)
- Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial (2018)
Immediate Impact
1 by Nobel laureates 8 from Science/Nature 61 standout
Citing Papers
Multidrug-resistant Gram-negative bacterial infections
2025 Standout
Interferon- γ and infectious diseases: Lessons and prospects
2024 StandoutScience
Works of Simon Portsmouth being referenced
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase–Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies
2022
Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Simon Portsmouth | 1402 | 774 | 349 | 817 | 61 | 2.8k | |
| Bruce Polsky | 1344 | 774 | 433 | 699 | 76 | 2.9k | |
| Robert C. Kalayjian | 1073 | 1482 | 922 | 863 | 82 | 3.5k | |
| Athanasios Skoutelis | 1166 | 712 | 125 | 723 | 94 | 2.7k | |
| Joan R. Butterton | 1208 | 1049 | 127 | 781 | 85 | 3.1k | |
| Vicente Pintado | 1459 | 1267 | 359 | 722 | 75 | 3.1k | |
| Sandra L. Preston | 931 | 509 | 223 | 668 | 44 | 2.3k | |
| Julián Torre‐Cisneros | 2747 | 1597 | 129 | 1170 | 140 | 4.6k | |
| Shalom Z. Hirschman | 1191 | 747 | 298 | 363 | 110 | 3.5k | |
| Glenn Wortmann | 1039 | 696 | 264 | 549 | 86 | 2.6k | |
| Mina Psichοgiou | 1237 | 822 | 239 | 1265 | 101 | 2.9k |
All Works
Login with ORCID to disown or claim papers
Loading papers...